Kallidinogenase (Tissue Kallikrien) in Complex Therapy in Patients with Isolated Closed Traumatic Brain Injury

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/6201

Full metadata record

DC Field	Value	Language
dc.contributor.author	Аvakov V. E., Ibragimov N. K., Murotov TM. N.	-
dc.date.accessioned	2023-01-30T06:25:02Z	-
dc.date.available	2023-01-30T06:25:02Z	-
dc.date.issued	2022-12-04	-
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/6201	-
dc.description.abstract	Closed isolated traumatic brain injury (ТBI) is a major medical and social problem due to its high prevalence, high rates of mortality and disability, as well as the economic costs of treatment, rehabilitation and social assistance to victims [1]. Considering the severity of this disease and the insufficient effectiveness of conventional methods of treatment, we studied the effectiveness of the drug Kallidinogenase (tissue kallikrein) in complex therapy in patients with closed isolated traumatic brain injury.	en_US
dc.language.iso	en_US	en_US
dc.publisher	American Journal of Medicine and Medical Sciences	en_US
dc.subject	CTBI, Tissue kallikrein (kallidinogenase), ICP, CPP, GLASGOW scale, SAPS II, APACHE II	en_US
dc.title	Kallidinogenase (Tissue Kallikrien) in Complex Therapy in Patients with Isolated Closed Traumatic Brain Injury	en_US
dc.type	Article	en_US
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
128.pdf	Kallidinogenase (Tissue Kallikrien) in Complex Therapy in Patients with Isolated Closed Traumatic Brain Injury	294.45 kB	Adobe PDF	View/Open

DSpace JSPUI